CATALOGO DEI PRODOTTI DELLA RICERCA

Carbognin, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.009
NA - Nord America 1.944
AS - Asia 1.360
SA - Sud America 166
AF - Africa 42
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.526
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.908
RU - Federazione Russa 855
CN - Cina 453
SG - Singapore 447
GB - Regno Unito 387
IT - Italia 169
VN - Vietnam 140
SE - Svezia 130
DE - Germania 126
BR - Brasile 123
HK - Hong Kong 107
IE - Irlanda 98
FR - Francia 95
KR - Corea 58
FI - Finlandia 48
IN - India 40
NL - Olanda 26
JP - Giappone 23
UA - Ucraina 19
BD - Bangladesh 14
AR - Argentina 13
CA - Canada 13
TR - Turchia 12
MX - Messico 10
PL - Polonia 10
PK - Pakistan 9
ZA - Sudafrica 9
EC - Ecuador 8
ES - Italia 8
ID - Indonesia 8
NG - Nigeria 8
UZ - Uzbekistan 7
VE - Venezuela 7
MA - Marocco 6
IQ - Iraq 5
SA - Arabia Saudita 5
AL - Albania 4
AT - Austria 4
CH - Svizzera 4
GR - Grecia 4
PT - Portogallo 4
AU - Australia 3
BJ - Benin 3
BO - Bolivia 3
CO - Colombia 3
CY - Cipro 3
DZ - Algeria 3
EG - Egitto 3
IR - Iran 3
JM - Giamaica 3
KZ - Kazakistan 3
LT - Lituania 3
MY - Malesia 3
PY - Paraguay 3
RO - Romania 3
TG - Togo 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BE - Belgio 2
CL - Cile 2
CR - Costa Rica 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
TW - Taiwan 2
AZ - Azerbaigian 1
BS - Bahamas 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GF - Guiana Francese 1
HT - Haiti 1
IL - Israele 1
JO - Giordania 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
ME - Montenegro 1
MM - Myanmar 1
MT - Malta 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
TH - Thailandia 1
WS - Samoa 1
Totale 5.526
Salva come PNG Salva come JPEG
Città #
Southend 328
Moscow 307
Chandler 263
Ashburn 215
Singapore 209
San Jose 181
Woodbridge 133
Dallas 126
Hong Kong 104
Beijing 99
Dublin 96
New York 81
Verona 69
The Dalles 64
Ho Chi Minh City 60
Jacksonville 57
Los Angeles 46
Munich 45
Ann Arbor 44
Lawrence 31
Princeton 31
Hanoi 30
Wilmington 28
Jinan 25
Shenyang 25
Nanjing 23
Tianjin 23
Seoul 22
Santa Clara 21
Orem 19
Chennai 18
Tokyo 18
Turku 18
London 17
Buffalo 15
Columbus 15
Redondo Beach 15
Guangzhou 14
Council Bluffs 13
Frankfurt am Main 13
Hebei 13
Houston 13
Denver 12
São Paulo 12
Zhengzhou 12
Sindelfingen 11
Changsha 10
Abuja 8
Manchester 8
Mexico City 8
Mumbai 8
Ningbo 8
Seattle 8
Amsterdam 7
Atlanta 7
Barnet 7
Brooklyn 7
Milan 7
Rome 7
San Francisco 7
Stockholm 7
Tashkent 7
Haikou 6
Hangzhou 6
Helsinki 6
Johannesburg 6
Nanchang 6
Paris 6
Taiyuan 6
Biên Hòa 5
Boston 5
Markgröningen 5
Montreal 5
Redmond 5
Redwood City 5
Rio de Janeiro 5
Shanghai 5
Warsaw 5
Acalanes Ridge 4
Augusta 4
Cagliari 4
Campo Grande 4
Dearborn 4
Haiphong 4
Hải Dương 4
Lancaster 4
Marseille 4
Meda 4
New Delhi 4
Phoenix 4
Poplar 4
Taizhou 4
Thái Nguyên 4
Ankara 3
Athens 3
Bologna 3
Charlotte 3
Clearwater 3
Cotonou 3
Detroit 3
Totale 3.323
Salva come PNG Salva come JPEG
Nome #
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 219
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 212
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 207
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 200
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 200
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 196
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 187
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 187
Identification of clinical, pathological and molecular predictors of prognosis in early-stage invasive lobular breast cancer: role of proliferation and CDK4/6 pathway. 184
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 184
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 179
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 172
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 169
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 164
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 164
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 161
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 160
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 157
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 155
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 150
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 145
Muscle derangement and alteration of the nutritional machinery in NSCLC 144
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 141
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 139
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 136
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 133
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 131
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 131
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma 126
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 126
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories 119
Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success 114
The obesity paradox in cancer: clinical insights and perspectives 112
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. 99
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 60
Totale 5.594
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.299
article - articoli 17.288
book - libri 0
conference - conferenze 553
curatela - curatele 0
other - altro 458
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202137 0 0 0 0 0 0 0 0 0 5 26 6
2021/2022269 20 92 0 33 11 3 3 8 13 6 15 65
2022/2023645 36 90 39 134 57 151 3 37 64 1 20 13
2023/2024355 14 24 16 27 54 75 7 32 10 34 55 7
2024/2025812 38 33 44 158 26 38 16 20 138 56 86 159
2025/20262.481 178 103 150 452 743 142 188 129 233 163 0 0
Totale 5.594